Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
Attard
Gerhardt
G
Institute for Cancer Research/The Royal Marsden NHS Foundation Trust, Centre for Cancer Therapeutics, Sutton, Surrey, UK. Gerhardt.attard@icr.ac.uk
Belldegrun
Arie S
AS
de Bono
Johann S
JS
D000726:Androgen Antagonists / Q000627:therapeutic use*; D059002:Androgen Receptor Antagonists; D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use*; D000818:Animals; D004341:Drug Evaluation; D006801:Humans; D008190:Lyases / Q000037:antagonists & inhibitors*; D008297:Male; D051379:Mice; D009362:Neoplasm Metastasis / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D013254:Steroid 17-alpha-Hydroxylase / Q000502:physiology
D000726:Androgen Antagonists; D059002:Androgen Receptor Antagonists; D000736:Androstenes; D000737:Androstenols; D013254:Steroid 17-alpha-Hydroxylase; D008190:Lyases; C089740:abiraterone